Logo image of CDMO

AVID BIOSERVICES INC (CDMO) Stock Fundamental Analysis

NASDAQ:CDMO - Nasdaq - US05368M1062 - Common Stock - Currency: USD

12.49  +0.01 (+0.08%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CDMO. CDMO was compared to 568 industry peers in the Biotechnology industry. CDMO may be in some trouble as it scores bad on both profitability and health. CDMO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CDMO has reported negative net income.
In the past year CDMO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CDMO reported negative net income in multiple years.
Of the past 5 years CDMO 4 years had a positive operating cash flow.
CDMO Yearly Net Income VS EBIT VS OCF VS FCFCDMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

The Return On Assets of CDMO (-47.00%) is comparable to the rest of the industry.
With a Return On Equity value of -339.34%, CDMO is not doing good in the industry: 76.46% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -47%
ROE -339.34%
ROIC N/A
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
CDMO Yearly ROA, ROE, ROICCDMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

CDMO has a better Gross Margin (7.68%) than 73.81% of its industry peers.
CDMO's Gross Margin has declined in the last couple of years.
CDMO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
CDMO Yearly Profit, Operating, Gross MarginsCDMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

1

2. Health

2.1 Basic Checks

CDMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDMO has been increased compared to 1 year ago.
CDMO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CDMO is higher compared to a year ago.
CDMO Yearly Shares OutstandingCDMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CDMO Yearly Total Debt VS Total AssetsCDMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

CDMO has an Altman-Z score of -0.51. This is a bad value and indicates that CDMO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.51, CDMO is in the better half of the industry, outperforming 61.95% of the companies in the same industry.
A Debt/Equity ratio of 3.58 is on the high side and indicates that CDMO has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.58, CDMO is doing worse than 84.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.58
Debt/FCF N/A
Altman-Z -0.51
ROIC/WACCN/A
WACC8.72%
CDMO Yearly LT Debt VS Equity VS FCFCDMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.30 indicates that CDMO should not have too much problems paying its short term obligations.
CDMO's Current ratio of 1.30 is on the low side compared to the rest of the industry. CDMO is outperformed by 83.89% of its industry peers.
A Quick Ratio of 0.92 indicates that CDMO may have some problems paying its short term obligations.
CDMO's Quick ratio of 0.92 is on the low side compared to the rest of the industry. CDMO is outperformed by 87.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.92
CDMO Yearly Current Assets VS Current LiabilitesCDMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for CDMO have decreased strongly by -1305.88% in the last year.
The Revenue for CDMO has decreased by -15.80% in the past year. This is quite bad
Measured over the past years, CDMO shows a very strong growth in Revenue. The Revenue has been growing by 21.15% on average per year.
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%

3.2 Future

CDMO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.71% yearly.
Based on estimates for the next years, CDMO will show a very strong growth in Revenue. The Revenue will grow by 22.14% on average per year.
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CDMO Yearly Revenue VS EstimatesCDMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CDMO Yearly EPS VS EstimatesCDMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDMO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDMO Price Earnings VS Forward Price EarningsCDMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDMO Per share dataCDMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

CDMO's earnings are expected to grow with 27.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.79%
EPS Next 3Y27.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDMO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVID BIOSERVICES INC

NASDAQ:CDMO (2/4/2025, 8:00:02 PM)

12.49

+0.01 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-10 2024-12-10/amc
Earnings (Next)04-22 2025-04-22/amc
Inst Owners105.25%
Inst Owner Change-1.94%
Ins Owners0.95%
Ins Owner Change-5994.99%
Market Cap801.11M
Analysts74.55
Price Target12.75 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-92.85%
Min EPS beat(2)-125.28%
Max EPS beat(2)-60.43%
EPS beat(4)0
Avg EPS beat(4)-1306.42%
Min EPS beat(4)-4971.9%
Max EPS beat(4)-60.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-3.38%
Max Revenue beat(2)-2.89%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-3.38%
Max Revenue beat(4)-0.02%
Revenue beat(8)3
Avg Revenue beat(8)-3.35%
Revenue beat(12)7
Avg Revenue beat(12)0.75%
Revenue beat(16)11
Avg Revenue beat(16)3.84%
PT rev (1m)0%
PT rev (3m)-7.41%
EPS NQ rev (1m)-9.09%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-1.69%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.32
P/FCF N/A
P/OCF 152.36
P/B 17.88
P/tB 17.88
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.08
OCFY0.66%
SpS2.35
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47%
ROE -339.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.68%
FCFM N/A
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 3.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 119.78%
Cap/Sales 9.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 0.92
Altman-Z -0.51
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)874.1%
Cap/Depr(5y)606.28%
Cap/Sales(3y)40.63%
Cap/Sales(5y)27.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%
EBIT growth 1Y-69.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y71.06%
EBIT Next 5YN/A
FCF growth 1Y89.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y277.64%
OCF growth 3Y-29.44%
OCF growth 5YN/A